| Name | Title | Contact Details |
|---|---|---|
Larry Rogers |
Chief Information Officer | Profile |
Doug Carroll |
Chief Information Security Officer | Profile |
Founded in 1950, Miami Children's Hospital is South Florida’s only licensed specialty hospital exclusively for children. The 289-bed hospital is renowned for excellence in all aspects of pediatric medicine with several specialty programs ranked among the best in the nation in 2010 by U.S.News & World Report. The hospital has also been designated an American Nurses Credentialing Center (ANCC) Magnet facility, the nursing profession’s most prestigious institutional honor and is home to the largest pediatric teaching program in the southeastern United States. With a medical staff of more than 650 physicians and over 2,000 employees, the hospital is renowned for excellence in all aspects of pediatric medical care from birth through adolescence, offering more than 40 pediatric specialties and subspecialties, and is home to Florida’s only free-standing pediatric trauma center.
HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
eScribe provides industry-leading scribe staffing for hospitals and physician-owned groups across the nation in a variety of emergency medicine and outpatient settings. eScribe has a proven track record in creating programs that are financially viable and produce a sustainable, positive return on investment for its partners.
HASTINGS and PRINCE ED CNTY HLTH is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.